

Jennifer Knox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12181329/publications.pdf>

Version: 2024-02-01

19
papers

4,982
citations

623188

14
h-index

794141

19
g-index

19
all docs

19
docs citations

19
times ranked

6581
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	1.3	43
2	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	7
3	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
4	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	2.0	51
5	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	1.9	32
6	Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2136-2143.	0.5	7
7	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
8	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1112-1129.	7.7	676
9	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816
10	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. <i>Oncotarget</i> , 2018, 9, 20439-20450.	0.8	21
11	Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1303-1311.	0.7	17
12	Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 580-587.	0.4	103
13	Consensus Conference on Gallbladder Cancer. <i>Hpb</i> , 2015, 17, 664-665.	0.1	5
14	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	0.9	41
15	Patterns of care and treatment outcomes in older patients with biliary tract cancer. <i>Oncotarget</i> , 2015, 6, 44995-45004.	0.8	27
16	Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4504.	0.8	45
17	Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4565-4565.	0.8	4
18	Malignant Intracardiac Thrombus from Hepatocellular Carcinoma Treated with External Beam Radiation Therapy. <i>Journal of Palliative Medicine</i> , 2010, 13, 1293-1295.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 657-664.	0.8	541